CD226 and diffuse large B-cell lymphoma: Furthermore, DLBCL patients with high-risk prognostic scores exhibited higher TIGIT and lower CD226 expression, which correlated with more severe NK cell impairment, suggesting a potential role of these molecules in disease progression.